JP2002533346A5 - - Google Patents

Download PDF

Info

Publication number
JP2002533346A5
JP2002533346A5 JP2000589543A JP2000589543A JP2002533346A5 JP 2002533346 A5 JP2002533346 A5 JP 2002533346A5 JP 2000589543 A JP2000589543 A JP 2000589543A JP 2000589543 A JP2000589543 A JP 2000589543A JP 2002533346 A5 JP2002533346 A5 JP 2002533346A5
Authority
JP
Japan
Prior art keywords
formula
compound
lower alkyl
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000589543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002533346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/010129 external-priority patent/WO2000037473A1/en
Publication of JP2002533346A publication Critical patent/JP2002533346A/ja
Publication of JP2002533346A5 publication Critical patent/JP2002533346A5/ja
Pending legal-status Critical Current

Links

JP2000589543A 1998-12-22 1999-12-20 エポシロン誘導体およびそれらの抗腫瘍剤としての使用 Pending JP2002533346A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH2530/98 1998-12-22
CH253098 1998-12-22
PCT/EP1999/010129 WO2000037473A1 (en) 1998-12-22 1999-12-20 Epothilone derivatives and their use as antitumor agents

Publications (2)

Publication Number Publication Date
JP2002533346A JP2002533346A (ja) 2002-10-08
JP2002533346A5 true JP2002533346A5 (cg-RX-API-DMAC10.html) 2007-01-25

Family

ID=4235876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589543A Pending JP2002533346A (ja) 1998-12-22 1999-12-20 エポシロン誘導体およびそれらの抗腫瘍剤としての使用

Country Status (12)

Country Link
US (1) US6387927B1 (cg-RX-API-DMAC10.html)
EP (1) EP1140944B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002533346A (cg-RX-API-DMAC10.html)
CN (1) CN1122668C (cg-RX-API-DMAC10.html)
AT (1) ATE248175T1 (cg-RX-API-DMAC10.html)
AU (1) AU2795000A (cg-RX-API-DMAC10.html)
BR (1) BR9916833A (cg-RX-API-DMAC10.html)
CA (1) CA2352505C (cg-RX-API-DMAC10.html)
DE (1) DE69910831T2 (cg-RX-API-DMAC10.html)
ES (1) ES2207983T3 (cg-RX-API-DMAC10.html)
PT (1) PT1140944E (cg-RX-API-DMAC10.html)
WO (1) WO2000037473A1 (cg-RX-API-DMAC10.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186606B2 (de) 1995-11-17 2011-09-07 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate, ihre Herstellung und Verwendung
CN1196698C (zh) 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US20020111317A1 (en) * 2000-09-25 2002-08-15 Leonard Katz Sixteen-membered macrolide compounds
WO2002062338A1 (en) 2001-01-25 2002-08-15 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
KR20040025895A (ko) 2001-02-20 2004-03-26 브리스톨-마이어스스퀴브컴파니 에포틸론 유도체를 사용하는 치료불응성 종양의 치료
BRPI0207961B8 (pt) 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CZ302848B6 (cs) * 2001-03-19 2011-12-14 Novartis Ag Kombinace protiprujmového cinidla a derivátu epothilonu
EP1392664A4 (en) 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
JPWO2003031414A1 (ja) * 2001-10-03 2005-01-20 日本曹達株式会社 新規なヘテロ環化合物および抗炎症薬
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
WO2003077903A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ES2281692T3 (es) 2002-08-23 2007-10-01 Sloan-Kettering Institute For Cancer Research Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
HRP20050278A2 (en) 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
US7112581B2 (en) 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
DE10256982A1 (de) * 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1845096A1 (en) * 2006-03-27 2007-10-17 ETH Zürich 12-Aza-epothilones, process for their preparation and their use as antiproliferative agents
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc BINDING COMPOUNDS TO THE IAP BIR DOMAIN
DE102007016046A1 (de) 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
CN101519404B (zh) * 2008-02-29 2016-01-20 唐莉 15环噻酮衍生物及其制备方法与应用
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives

Similar Documents

Publication Publication Date Title
JP2002533346A5 (cg-RX-API-DMAC10.html)
JP6622824B2 (ja) キヌレニン−3−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
EP2331538B1 (en) Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
JP2002533346A (ja) エポシロン誘導体およびそれらの抗腫瘍剤としての使用
KR20080040046A (ko) 티아졸 유도체
WO2019015559A1 (zh) 作为ask抑制剂的杂环化合物及其应用
CN111108092A (zh) 芳酰胺类Kv2.1抑制剂及其制备方法、药物组合物和用途
JPH10512257A (ja) 置換オキサゾリジンカルパインおよび/またはカテプシンb阻害剤
HK1224288A1 (zh) 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN102498105A (zh) 双环化合物及其医疗用途
JPH04230681A (ja) 1,4‐ベンゾチアゼピン誘導体
JP2019518779A (ja) アルドース還元酵素阻害剤およびその使用方法
WO2009105969A1 (zh) 15环噻酮化合物及其制备方法与应用
CN111225917A (zh) 取代咪唑并吡啶酰胺及其用途
JP2680196B2 (ja) 血小板凝集阻害作用を有する新規化合物
EP1807421A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
WO1997005902A1 (fr) Composition medicinale
JPH05222020A (ja) エイズの治療に有用なhivプロテアーゼインヒビター
JP2001508418A (ja) ヒトサイトメガロウイルスプロテアーゼのペプチドミメティックインヒビター
HUT65660A (en) Process for preparing quinolyl-methoxy-phenyl-acetamide derivatives substituted with heterocycles and pharmaceutical compositions containing them
JP4647726B2 (ja) 新規なアニリド化合物及びこれを含有する医薬
WO2003066671A1 (en) Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof
RU2015980C1 (ru) 7-оксабициклогептилзамещенные гетероциклические амиды или их стереоизомеры в качестве антагонистов рецепторов тромбоксана
KR102437095B1 (ko) 캐스파제 저해제의 프로드럭
CN101203498A (zh) 包括可代谢部分的杂环抗病毒化合物及其用途